FRACTIONAL CHIEF COMMERCIAL OFFICER FOR BIOTECH
The decisions you make today determine commercial success years from now.
For scientific founders and biotech CEOs facing commercial questions they have never had to answer before.
THE POINT OF VIEW
Commercial success is won or lost years before launch.
It is shaped by the quality of the decisions a company makes when uncertainty is highest and there is no playbook to follow. By the time most companies hire a commercial leader, the calls that matter most have already been made.
Scientific rigor got the asset here. Commercial rigor determines what it becomes.
“We’ll figure that out later” is one of
the most expensive phrases in biotech.
WHAT I HELP YOU DECIDE
High-consequence commercial decisions, made years before launch
01
Which asset or indication should we prioritize?
02
How do we position this asset to win?
03
How do we make the commercial case to the board, investors, and partners, so it holds up under scrutiny?
04
When do we start building commercial capability, and in what order?
HOW I WORK
The Sightline Method
How Kavros Advisors helps leadership teams make the commercial decisions that determine success years before launch.
WAYS TO WORK TOGETHER
From a single decision to ongoing leadership
Start with the single decision in front of you, or bring in ongoing, fractional commercial leadership. Each engagement is built around the decision and the value at stake.
On-ramp
The Decision Frame
Turn a fuzzy question into a sharply framed decision.
Core engagement
The Decision Partnership
One decision, resolved into a board-ready recommendation.
Ongoing counsel
The Commercial Advisor
Judgment on call as decisions arise.
Embedded
The Fractional CCO
CCO-level leadership, years before a full-time hire.
CASE STUDIES
Decisions that changed the trajectory
Featured
Advanced Therapy · Oncology
Setting the launch footprint for a first-in-class advanced therapy.
A critical, hard-to-reverse commercial decision, made years before launch.
ABOUT
Heather Aspras
Heather Aspras is the founder of Kavros Advisors and a fractional Chief Commercial Officer for biotech. She has spent more than two decades in biopharma commercial strategy, spanning portfolio strategy, new product planning, pre-launch strategy, and commercial build-out across a range of therapeutic areas, including oncology, vaccines, and advanced therapies.
She has done that work at both ends of the industry, in global pharma organizations with established commercial models and in an early-stage biotech where she built the marketing team from scratch.
She serves on the External Review Committee for the Healthcare Investment Group at Ben Franklin Technology Partners of Southeastern Pennsylvania. She holds an AB summa cum laude from Princeton University and an MBA with honors from The Wharton School.
If you are facing one of
those decisions, let's talk.
A short, practical conversation about the calls in front of you and
where a commercial view would help most.